There are 2789 resources available
1045P - Comparison between first-line target therapy and immunotherapy in different prognostic categories of BRAF mutant metastatic melanoma patients
Presenter: Riccardo Marconcini
Session: ePoster Display
1046P - First-line anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy in Japanese mucosal melanoma: A retrospective, multicenter study (JMAC study)
Presenter: Yasuhiro Nakamura
Session: ePoster Display
1047P - Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
Presenter: Prachi Bhave
Session: ePoster Display
1048P - Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Presenter: Jeeyun Lee
Session: ePoster Display
1049P - Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)
Presenter: Florentia Dimitriou
Session: ePoster Display
1050P - Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors
Presenter: Arkhjamil Angeles
Session: ePoster Display
1051P - Impacts of skeletal muscle on survival in resected stage III malignant melanoma
Presenter: Susie Youn
Session: ePoster Display
1052P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: ePoster Display
1053P - Tumour mutational burden (TMB) assessment using next generation sequencing (NGS) for the prediction of complete response (CR) to immunotherapy (IO) in metastatic melanoma
Presenter: Timothy Humphries
Session: ePoster Display
1054P - FDG-PET to predict long-term outcome from anti-PD1 (PD1) therapy in metastatic melanoma
Presenter: Florentia Dimitriou
Session: ePoster Display